上海惠盾生物技术

Huidun Biotech (Shanghai Humantech Biotechnology) is a research-driven, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutic vaccines and cell therapies. The company leverages three core proprietary technology platforms: PTVax (protein therapeutic vaccine platform), CTVax (cell therapeutic vaccine platform), and RTVax (mRNA therapeutic vaccine platform). Its pipeline targets high-need areas in oncology, autoimmune diseases, and metabolic disorders. Key clinical assets include Gelidengsai (格乐登赛), a tumor vaccine in Phase 2 development for glioblastoma and hepatocellular carcinoma, and Prodencel (普乐登赛), an autologous dendritic cell vaccine in Phase 1 for prostate cancer.